Studies on the chemotherapy of malaria. (III). Treatment of falciparum malaria in the Gambia, with BRL 50216 (4,6-diamino-(3, 4-dichlorobenzyloxy)-1,2-dihydro-2 2-dimethyl-1,3,5-triazine hydrochloride) alone and in combination with sulphonamides,.
D000284:Administration, Oral; D001593:Benzyl Compounds / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005493:Folic Acid Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005714:Gambia; D006400:Hematocrit; D006452:Hemoglobinometry; D006801:Humans; D007223:Infant; D008218:Lymphocytosis / Q000139:chemically induced; D008288:Malaria / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D010963:Plasmodium falciparum / Q000302:isolation & purification*; D013412:Sulfadimethoxine / Q000008:administration & dosage; D013444:Sulfisoxazole / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage* / Q000627:therapeutic use; D014227:Triazines / Q000008:administration & dosage*
D001593:Benzyl Compounds; D005493:Folic Acid Antagonists; D013449:Sulfonamides; D014227:Triazines; D013412:Sulfadimethoxine; D013444:Sulfisoxazole